Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)

Part of paid clinical trials in Houston, Texas.

Sponsor
The University of Texas Health Science Center, Houston
Study ID
NCT06280482
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Smooth Muscle Dysfunction Syndrome (SMDS)

Eligibility Criteria

Sex
ALL
Age
1 Year - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nicotinamide riboside (NR) — DRUG
    Participants will take their weight-based dose of NR once daily by mouth with food for 60 days.

Study Details

The purpose of this study is to determine whether SMDS patients treated with NR at the proposed dose exhibit decreased glucose uptake in the aorta, to determine if NR treatment results in measurable changes of blood NAD+ and NR levels, to determine if aortic measurements are stable after treatment with NR and to evaluate the safety and tolerability of NR in SMDS patients.

Key Dates

Start date
Mar 6, 2024
Status verified
Sep 2025
Primary completion
Jul 25, 2027
Completion
Jul 25, 2027

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment

Primary Outcome Measure

Change in systolic blood [ Time Frame: Baseline , 8 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Texas Health Science Center at HoustonHoustonTexas77030
Dianna Milewicz, MD, PhD
[email protected]
713-500-6725
David Murdock, MD
[email protected]
(713) 500-6735

Find similar trials in Houston, TX

By research site
The University of Texas Health Science Center at Houston· Houston, TX